CONCLUSION. Upon baricitinib treatment, clinical manifestations and inflammatory and IFN biomarkers improved in patients with the monogenic interferonopathies CANDLE, SAVI, and other interferonopathies. The gene discussed is IFNA1; the disease is STING-associated vasculopathy with onset in infancy.